Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Berrino F, De AR, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Survival for eight major cancers and all cancers combined for European adults disgnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007;8:773–83.
   PubMed Web of Science ®Google Scholar
• Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007;8:784–96.
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653–60.
   PubMed Web of Science ®Google Scholar
• Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growht factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000;124:1061–5.
   PubMed Web of Science ®Google Scholar
• Iavarone M, Lampertico P, Iannuzzi F, Manenti E, Donato MF, Arosio E, Increased expression of vascular endothelial growht factor in small hepatocellular carcinoma. J Viral Hepat 2007;14:133–9.
   PubMed Web of Science ®Google Scholar
• Jinno K, Tanimizu M, Hyodo I, Nishikawa Y, Hosokawa Y, Doi T, Circulating vascular endothelial growht factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998;33:376–82.
   PubMedGoogle Scholar
• Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55–60.
   PubMed Web of Science ®Google Scholar
• Holash J, Wiegand SJ, Yancopoulos GD. New model of tumour angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999;18:5356–62.
   PubMed Web of Science ®Google Scholar
• Zhang ZL, Liu ZS, Sun Q. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 2006;12:4241–5.
   PubMed Web of Science ®Google Scholar
• Torimura T, Ueno T, Kin M, Harada R, Taniguchi E, Nakamura T, Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol 2004;40:799–807.
   PubMed Web of Science ®Google Scholar
• Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M, Tsuneyoshi M. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol 2003;56:854–60.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341–5.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi N, Shimizu H, Ohtsuka M, Wakabayashi Y, Ito H, Kimura F, Angiopoietins and Tie2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003;37:1105–13.
   PubMed Web of Science ®Google Scholar
• Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1α. Liver Int 2006;26:414–23.
   PubMed Web of Science ®Google Scholar
• Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Overexpression of VEGF and Angiopoietin 2: a key to high vascularity of hepatoellular carcinoma? Mod Pathol 2003;16:552–7.
   PubMed Web of Science ®Google Scholar
• Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumour angiogenesis in gastric carcinoma: posible in vivo regulation via induction of proteases. Cancer Res 2001;61:2145–53.
   PubMed Web of Science ®Google Scholar
• Ahmad SA, Liu W, Jung ID, Fan F, Reinmuth N, Bucana CD, Differential expression of angiopoietin-1 and angiopoietin-2 in colorectal carcinoma. Cancer 2001;92:1138–43.
   PubMed Web of Science ®Google Scholar
• Sfiligoi C, De Luca A, Cascone I, Sorbello V, Fuso L, Ponzone R, Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 2003;103:466–74.
   PubMed Web of Science ®Google Scholar
• Lind AJ, Wikstrom P, Granfors T, Egevad L, Stattin P, Bergh A. Angiopoietin 2 expression is related to histological grade, vascular density, metastases and outcome in prostate cancer. Prostate 2005;62:394–9.
   PubMed Web of Science ®Google Scholar
• Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama HO, Kagawa S. Expression of angiopoietin-1 and -2 and its clinical significance in human bladder cancer. BJU Int 2005;95:660–3.
   PubMedGoogle Scholar
• Scholz A, Rehm VA, Rieke S, Derkow K, Schulz P, Neumann K, Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 2007;102:2471–81.
   PubMed Web of Science ®Google Scholar
• Kuboki S, Shimizu H, Mitsuhashi N, Kusashio K, Kimura F, Yoshidome H, Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinoma. J Gastroenterol Hepatol 2008;23:e157–64.
   Google Scholar
• Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–70.
   PubMed Web of Science ®Google Scholar
• Child CG, Turcotte JC. Surgery and portal hypertension. Major Probl Clin Surg 1964;1:1–85.
   PubMedGoogle Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–36.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19:329–38.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52–60.
   PubMed Web of Science ®Google Scholar
• Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient anything worth doing should be done right. Hepatology 2004;39:280–2.
   PubMed Web of Science ®Google Scholar
• Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161–9.
   PubMed Web of Science ®Google Scholar
• Huang GW, Yang LY, Lu WQ. Expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J Gastroenterol 2005;11:1705–8.
   PubMed Web of Science ®Google Scholar
• Salcedo Mora X, Sanz-Cameno P, Medina J, Martin-Vilchez S, Garcia-Buey L, Borque MJ, Association between angiogenesis soluble factors and disease progression markers in chronic hepatitis C patients. Rev Esp Enferm Dig 2005;97:699–706.
   PubMedGoogle Scholar
• Salcedo X, Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-Vilchez M, Borque MJ, The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 2005;42:696–701.
   PubMedGoogle Scholar
• Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009;50:923–8.
   PubMed Web of Science ®Google Scholar
• Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481–8.
   PubMed Web of Science ®Google Scholar
• Ripoll C, Bañares R, Rincón D, Catalina MV, Lo Iacono O, Salcedo M, Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology 2005;42:793–801.
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000;14:1983–91.
   PubMed Web of Science ®Google Scholar
• Krikun G, Schatz F, Finlay T, Kadner S, Mesia A, Gerrets R, Expression of angiopoietin-2 by human endometrial endothelial cells: regulation by hypoxia and inflammation. Biochem Biophys Res Commun 2000;275:159–63.
   PubMed Web of Science ®Google Scholar
• Koga K, Todaka T, Morioka M, Hamada J, Kai Y, Yano S, Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 2001;61:6248–54.
   PubMed Web of Science ®Google Scholar
• Currie MJ, Gunningham SP, Turner K, Han C, Scott PA, Robinson BA, Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol 2002;198:502–10.
   PubMed Web of Science ®Google Scholar